Amniotic membrane extract polypeptide hydrogel as well as preparation method and application thereof

Through freeze-thaw treatment and peptide hydrogel technology, amniotic extract polypeptide hydrogel was prepared, which solved the problem of easy loss of active ingredients of amniotic extract and short shelf life, achieved sustained release and long-term preservation of drugs, and improved the corneal repair effect .

CN118987044APending Publication Date: 2024-11-22TIANJIN EYE HOSPITAL
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411119433.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The active ingredients of existing amniotic extracts are easily lost, have a short shelf life, are difficult to store for a long time, and there are problems such as infection risk and vision loss in clinical applications, and there is a lack of effective drug forms.

Method used

The fibroblast layer and sponge layer were removed by freeze-thawing treatment, and combined with the polypeptide hydrogel technology, an amniotic extract polypeptide hydrogel was prepared to achieve sustained release and long-term preservation of drug active ingredients.

Benefits of technology

It improves the concentration and shelf life of the active ingredient of amniotic extracts, reduces the risk of infection, provides a homogeneous and transparent drug form, enhances the corneal repair effect, and solves the preservation and use problems in clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987044A_ABST
    Figure CN118987044A_ABST
Patent Text Reader

Abstract

The invention relates to amniotic membrane extract polypeptide hydrogel and a preparation method and application thereof.The preparation method of the amniotic membrane extract includes the steps that after amniotic membrane is frozen and thawed, a fibroblast layer and a spongy layer are torn off, remaining tissue is soaked in liquid nitrogen to be frozen and ground to obtain amniotic membrane powder, the amniotic membrane powder is mixed with normal saline, centrifugation is conducted after filtering, and supernatant is taken; and mixing the obtained amnion extract with polypeptide hydrogel with a specific concentration according to a ratio of 1: (2-4). According to the preparation method provided by the invention, the operation steps are simple, the active ingredients of the amnion are reserved to the greatest extent, and the prepared amnion extract polypeptide hydrogel has the effect of promoting corneal injury repair.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biomedical materials, and in particular to an amniotic membrane extract polypeptide hydrogel and a preparation method and application thereof. Background Art

[0002] In recent years, amniotic membrane transplantation has been performed clinically to promote corneal damage repair and reduce corneal opacity, and it has been increasingly widely used. Although amniotic membrane transplantation is a good method to promote corneal damage repair and reduce corneal opacity, there are many problems in clinical practice. For example, amniotic membrane needs to be prepared and stored in eye banks, which makes it difficult for primary hospitals to carry out the procedure. Amniotic membrane transplantation requires suture fixation, which may damage the ocular surface and increase the risk of infection. Since the amniotic membrane takes 2-3 weeks to be completely absorbed, the patient's vision may temporarily decrease after surgery. At the same time, many patients need to undergo multiple surgeries. Because its active ingredients are easily lost, finished amniotic membrane-related eye drops have not yet been developed.

[0003] The production processes of amniotic membrane extract (AME) are varied and unregulated, and most human placental membrane products lose activity after dehydration and irradiation. The effects of various methods of preserving amniotic membrane before AME production have not been fully studied, and after production, unpreserved drops have a short shelf life. How to properly preserve AME without affecting the effects of dehydration, irradiation or cryopreservation is a huge challenge. Each different method of processing and preserving AME may lead to changes in the structural or functional properties of various active biomolecules.

[0004] The human placental membrane products currently on the market include wet amniotic membrane and dry amniotic membrane, both of which are used for surgical sutures to fix on the surface of the eye, and there are no products for drug use. Currently, amniotic membrane extracts are being developed as drugs internationally, most of which are in the clinical trial stage, and there are no products on the market. These products are designed to be extremely inconvenient in terms of drug use. For example, some need to be freeze-dried for storage, and some need to be used within 7 days. This makes it difficult to ensure patient compliance and is not conducive to the function of the drug.

[0005] CN101040616A discloses a medicinal amniotic membrane and a preparation method thereof, wherein the medicinal amniotic membrane contains exogenous cell growth factors, and the preparation method thereof is to immerse the amniotic membrane in a preservation solution containing exogenous cell growth factors, and to store or freeze-dry the amniotic membrane at a deep low temperature. Not only can the amniotic membrane have biological activity after long-term preservation, but also the exogenous cell growth factors absorbed from the preservation solution can be slowly released onto the wound surface during use, which is beneficial to wound healing. This method requires the addition of additional chemical components and requires low-temperature preservation, which is relatively inconvenient.

[0006] In summary, how to provide an amniotic membrane extract with high active ingredient content, long shelf life and high stability, and apply it to promote corneal damage repair has become one of the urgent problems to be solved in this field. Summary of the invention

[0007] In order to solve the above technical problems, the present invention provides an amniotic membrane extract polypeptide hydrogel and a preparation method and application thereof. The operating steps for preparing the amniotic membrane extract are simple, and the active ingredients of the amniotic membrane are retained to the greatest extent. The amniotic membrane extract is mixed with a polypeptide solution to obtain an amniotic membrane extract polypeptide hydrogel. The polypeptide hydrogel can preserve the active ingredients of the drug and achieve sustained release of the drug, and has good biocompatibility, thereby solving the problem that the amniotic membrane cannot be preserved for a long time in clinical applications.

[0008] To achieve this object, the present invention adopts the following technical solutions:

[0009] In a first aspect, the present invention provides a method for preparing an amniotic membrane extract, comprising: freezing and thawing the amniotic membrane, tearing off the fibroblast layer and the sponge layer, freezing the remaining tissue in liquid nitrogen, grinding to obtain amniotic membrane powder, mixing with physiological saline, filtering and centrifuging to obtain the supernatant, and obtaining the amniotic membrane extract.

[0010] The amniotic membrane is divided into an epithelial cell layer, a basement membrane, a dense layer, a fibroblast layer and a spongy layer. The epithelial cell layer, the basement membrane and the dense layer have high structural homogeneity and contain the main active ingredients of the amniotic membrane. The present invention uses a freeze-thaw process to loosen the connection between the dense layer and the fibroblast layer, which can be directly torn off, thereby increasing the concentration of the active ingredients of the amniotic membrane.

[0011] Preferably, the freezing temperature during the freeze-thaw process is -20 to -40°C (for example, it may be -20°C, -22°C, -24°C, -26°C, -28°C, -30°C, -32°C, -34°C, -36°C, -38°C or -40°C, etc.).

[0012] Preferably, the freezing time during the freeze-thaw process is 12 to 20 h (for example, 12 h, 13 h, 14 h, 15 h, 16 h, 17 h, 18 h, 19 h or 20 h, etc.).

[0013] Preferably, the heating rate of thawing during the freeze-thaw process is 0.5 to 1°C / min (for example, 0.5°C / min, 0.55°C / min, 0.6°C / min, 0.65°C / min, 0.7°C / min, 0.75°C / min, 0.8°C / min, 0.85°C / min, 0.9°C / min, 0.95°C / min or 1°C / min, etc.);

[0014] Preferably, the final thawing temperature during the freeze-thaw process is 0-8°C (for example, 0°C, 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C or 8°C, etc.).

[0015] The present invention improves the efficiency of removing the fibroblast layer and the sponge layer by setting the freezing and thawing conditions during the freezing and thawing process.

[0016] Preferably, the method further comprises the step of flushing the amniotic membrane with a composite solution before freezing and thawing the amniotic membrane.

[0017] Preferably, the composite solution contains 50-150 μg / mL (for example, 50 μg / mL, 60 μg / mL, 70 μg / mL, 80 μg / mL, 90 μg / mL, 100 μg / mL, 110 μg / mL, 120 μg / mL, 130 μg / mL, 140 μg / mL or 150 μg / mL, etc.) gentamicin and 20-30 μg / mL (for example, 20 μg / mL, 21 μg / mL, 22 μg / mL, 23 μg / mL, 24 μg / mL, 25 μg / mL, 26 μg / mL, 27 μg / mL, 28 μg / mL, 29 μg / mL or 30 μg / mL, etc.) amphotericin B.

[0018] Preferably, after freezing and thawing the amniotic membrane, the method further comprises the step of flushing with physiological saline to remove the composite solution.

[0019] Preferably, a drying step is further included before obtaining the amniotic membrane extract.

[0020] Preferably, before the filtration, the mixture of amniotic membrane powder and physiological saline is also rotated and mixed at 80-120 r / min (for example, 80 r / min, 85 r / min, 90 r / min, 95 r / min, 100 r / min, 105 r / min, 110 r / min, 115 r / min or 120 r / min, etc.) at 0-8°C (for example, 0°C, 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C or 8°C, etc.) for 40-55 h (for example, 40 h, 42 h, 44 h, 46 h, 48 h, 50 h, 52 h or 55 h, etc.).

[0021] The invention ensures that the active components in the amniotic membrane are completely released and dissolved in the physiological saline by rotating and mixing the amniotic membrane powder and the physiological saline before filtering.

[0022] Preferably, the ratio of the amniotic membrane powder to physiological saline is 1 g: (2-4) mL.

[0023] The specific point values ​​of the above (2-4) can be selected as 2, 2.5, 2.8, 3, 3.2, 3.5 or 4, etc.

[0024] Preferably, the pore size of the filtration membrane is 50-100 μm (for example, it may be 50 μm, 60 μm, 70 μm, 80 μm, 90 μm or 100 μm, etc.).

[0025] Preferably, the centrifugal rotation speed is 2000-4000r / min (for example, it can be 2000r / min, 2200r / min, 2400r / min, 2600r / min, 2800r / min, 3000r / min, 3200r / min, 3400r / min, 3600r / min, 3800r / min or 4000r / min, etc.).

[0026] Preferably, the centrifugation time is 10 to 20 min (for example, it may be 10 min, 12 min, 14 min, 15 min, 16 min, 18 min or 20 min, etc.).

[0027] Preferably, the centrifugation temperature is 22-28°C (for example, it may be 22°C, 23°C, 24°C, 25°C, 26°C, 27°C or 28°C, etc.).

[0028] Preferably, the method for preparing the amniotic membrane extract comprises:

[0029] The amniotic membrane was bluntly separated from the placenta, and the amniotic membrane was rinsed with a compound solution containing 50-150 μg / mL gentamicin and 20-30 μg / mL amphotericin B, and frozen at -20--40°C for 12-20 h. The frozen amniotic membrane was thawed at a heating rate of 0.5-1°C / min to 0-8°C until it was completely thawed. The compound solution was rinsed with saline, and the fibroblast layer and sponge layer of the amniotic membrane were torn off. The remaining amniotic tissue (including epithelial cells) was removed. The amniotic membrane (amniotic membrane, basement membrane and dense layer) is immersed in liquid nitrogen for freezing, the frozen amniotic membrane is ground and then put into physiological saline, the ratio of amniotic membrane powder to physiological saline is 1g: (2-4)mL, and the mixture is rotated and mixed at 80-120r / min at 0-8°C for 40-55h, the liquid is filtered using a filter membrane with a pore size of 50-100μm, and centrifuged at 2000-4000r / min at 22-28°C for 10-20min, and the supernatant is taken to obtain the amniotic membrane extract.

[0030] In a second aspect, the present invention provides an amniotic membrane extract, which is prepared using the method for preparing the amniotic membrane extract described in the first aspect.

[0031] In a third aspect, the present invention provides an amniotic membrane extract polypeptide hydrogel, wherein the amniotic membrane extract polypeptide hydrogel contains the amniotic membrane extract and polypeptide solution described in the second aspect.

[0032] Preferably, the mass percentage of the polypeptide in the polypeptide solution is 0.5% to 2% (for example, it can be 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.6%, 1.8% or 2%, etc.).

[0033] Preferably, the amino acid sequence of the polypeptide includes the sequence shown in SEQ ID NO.1.

[0034] SEQ ID NO.1: FYIGSRGD.

[0035] Preferably, the amino terminus of the polypeptide is modified with biotin.

[0036] Preferably, the volume ratio of the amniotic membrane extract to the polypeptide solution is 1:(2-4).

[0037] The specific point values ​​of the above (2-4) can be selected as 2, 2.5, 2.8, 3, 3.2, 3.5 or 4, etc.

[0038] Preferably, the amniotic membrane extract polypeptide hydrogel is prepared by the following preparation method: stirring and mixing the amniotic membrane extract and the polypeptide solution at 0-8°C (for example, 0°C, 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C or 8°C, etc.).

[0039] In a fourth aspect, the present invention provides the use of any one or a combination of at least two of the preparation method of the amniotic membrane extract described in the first aspect, the amniotic membrane extract described in the second aspect, or the amniotic membrane extract polypeptide hydrogel described in the third aspect in the preparation of drugs for treating eye diseases.

[0040] Preferably, the eye disease includes any one or a combination of at least two of corneal injury, Sjögren's syndrome, dry eyes, corneal ulcer, chemical burns of the cornea and conjunctiva, or corneal erosion.

[0041] Other specific point values ​​within the above numerical ranges can be selected and will not be described in detail here.

[0042] Compared with the prior art, the present invention has the following beneficial effects:

[0043] (1) The present invention provides a method for preparing an amniotic membrane extract, which obtains a homogeneous and transparent amniotic membrane extract without requiring excessive steps such as chemical treatment. The operation steps are simple, the active ingredients of the amniotic membrane are retained to the greatest extent, and the transparency of the drug is improved.

[0044] (2) The present invention provides an amniotic membrane extract polypeptide hydrogel, which uses the polypeptide hydrogel to preserve the active ingredients of the drug and achieve sustained release of the drug, making full use of its good biocompatibility, solving the problem that the amniotic membrane cannot be preserved for a long time in clinical applications, and providing the possibility for the clinical application of the amniotic membrane's anti-scar, anti-angiogenesis, and repair-promoting effects as a drug in ophthalmology. The present invention further optimizes the dosage ratio of the amniotic membrane extract and the polypeptide hydrogel, so that the active ingredients of the drug are best preserved and the effect of promoting corneal repair is the strongest. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 This is the electron microscopic observation result of the amniotic membrane extract polypeptide hydrogel in Example 1;

[0046] Figure 2 This is a photo of the amniotic membrane extract polypeptide hydrogel of Example 1;

[0047] Figure 3 This is a transparency test result diagram of the amniotic membrane extract polypeptide hydrogel in Example 1;

[0048] Figure 4 This is a diagram showing the results of the corneal epithelial cell scratch test of the amniotic membrane extract polypeptide hydrogel in Example 1;

[0049] Figure 5 This is a curve diagram of HGF release from the amniotic membrane extract polypeptide hydrogel in Example 1;

[0050] Figure 6 This is a graph showing the changes in elastic modulus and viscous modulus of the amniotic membrane extract polypeptide hydrogel under different stresses in Example 1;

[0051] Figure 7 This is a graph showing the change in storage modulus and loss modulus over time under alternating high and low shear strains of the amniotic membrane extract polypeptide hydrogel in Example 1. DETAILED DESCRIPTION

[0052] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments and drawings. It should be understood that the specific implementation methods described herein are only used to explain the present invention, rather than to limit the present invention.

[0053] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0054] Preparation Example 1

[0055] This preparation example prepared an amniotic membrane extract, comprising the following steps:

[0056] After informed consent, placentas were collected from donors of elective caesarean sections, and serological screening was performed on the donors to exclude infectious diseases such as hepatitis B, syphilis, hepatitis C, and AIDS. After flushing the placenta to remove blood clots, amniotic membrane separation was performed by blunt separation. The amniotic membrane was rinsed and decontaminated with a composite solution containing 100 μg / mL gentamicin and 25 μg / mL amphotericin B, frozen at -30°C for 16 hours, and thawed at a heating rate of 0.7°C / min to 4°C until completely thawed. The composite solution was rinsed with saline to remove the fibroblast layer and sponge layer of the amniotic membrane, and the remaining amniotic tissue (epithelial cell layer, basement membrane, and dense layer) was immersed in liquid nitrogen for freezing, and ground to obtain amniotic membrane powder, which was mixed with saline at a ratio of 1 g: 3 mL, rotated and mixed at 100 r / min at 4°C for 48 hours, filtered using a 70 μm filter membrane, and centrifuged at 3000 r / min at 25°C for 15 minutes, and the supernatant was taken to obtain the amniotic membrane extract.

[0057] Preparation Example 2

[0058] This preparation example prepared an amniotic membrane extract, comprising the following steps:

[0059] After informed consent, placentas were collected from donors of elective caesarean sections, and serological screening was performed on the donors to exclude infectious diseases such as hepatitis B, syphilis, hepatitis C, and AIDS. After flushing the placenta to remove blood clots, amniotic membrane separation was performed by blunt separation. The amniotic membrane was rinsed and decontaminated with a composite solution containing 150 μg / mL gentamicin and 20 μg / mL amphotericin B, frozen at -40°C for 12 hours, and heated to 0°C at a heating rate of 1°C / min for thawing until completely thawed. The composite solution was removed by rinsing with physiological saline, the fibroblast layer and spongy layer of the amniotic membrane were torn off, and the remaining amniotic tissue (epithelial cell layer, basement membrane, and dense layer) was frozen in liquid nitrogen, ground to obtain amniotic powder, and the amniotic powder was mixed with physiological saline at a ratio of 1 g: 4 mL, rotated and mixed at 120 r / min at 0°C for 40 hours, filtered using a 100 μm filter membrane, centrifuged at 4000 r / min at 28°C for 10 minutes, and the supernatant was taken to obtain the amniotic extract.

[0060] Preparation Example 3

[0061] This preparation example prepared an amniotic membrane extract, comprising the following steps:

[0062] After informed consent, placentas were collected from donors of elective caesarean sections, and serological screening was performed on the donors to exclude infectious diseases such as hepatitis B, syphilis, hepatitis C, and AIDS. After flushing the placenta to remove blood clots, amniotic membrane separation was performed by blunt separation. The amniotic membrane was rinsed and decontaminated with a composite solution containing 50 μg / mL gentamicin and 30 μg / mL amphotericin B, frozen at -20°C for 20 hours, and thawed at a heating rate of 0.5°C / min to 8°C until completely thawed. The composite solution was removed by rinsing with physiological saline, the fibroblast layer and spongy layer of the amniotic membrane were torn off, and the remaining amniotic tissue (epithelial cell layer, basement membrane, and dense layer) was frozen in liquid nitrogen, ground to obtain amniotic powder, and the amniotic powder was mixed with physiological saline at a ratio of 1 g: 2 mL, and the mixture was rotated at 80 r / min at 8°C for 55 hours, filtered using a 50 μm filter membrane, and centrifuged at 2000 r / min at 22°C for 20 minutes. The supernatant was taken to obtain the amniotic extract.

[0063] Preparation Example 4

[0064] This preparation example prepared an amniotic membrane extract, which differed from Preparation Example 1 only in that the amniotic membrane was frozen for 10 hours after being flushed with the composite solution.

[0065] Preparation Example 5

[0066] This preparation example prepared an amniotic membrane extract, which differed from Preparation Example 1 only in that the amniotic membrane was frozen for 22 hours after being flushed with the composite solution.

[0067] Preparation Example 6

[0068] This preparation example prepared an amniotic membrane extract, which differed from Preparation Example 1 only in that the temperature of freezing the amniotic membrane after flushing it with the composite solution was -15°C.

[0069] Preparation Example 7

[0070] This preparation example obtains an amniotic membrane extract, which is different from the preparation example 1 only in that the temperature of freezing the amniotic membrane after flushing with the composite solution is -80°C.

[0071] Comparative Preparation Example 1

[0072] This comparative preparation example prepared an amniotic membrane extract, which differs from Preparation Example 1 only in that the fibroblast layer and the sponge layer of the amniotic membrane are not torn off after thawing.

[0073] Comparative Preparation Example 2

[0074] This comparative preparation example prepared an amniotic membrane extract, which differed from Preparation Example 1 only in that no freeze-thawing was performed, and the fibroblast layer and the sponge layer were manually scraped off.

[0075] Example 1

[0076] In this example, an amniotic membrane extract polypeptide hydrogel was prepared, comprising the following steps: at 4°C, the amniotic membrane extract obtained in Preparation Example 1 was mixed with a polypeptide aqueous solution containing 1% polypeptide by mass, the volume ratio of the amniotic membrane extract to the polypeptide solution was 1:3, and the polypeptide was biotin-FYIGSRGD.

[0077] Example 2

[0078] This example prepares an amniotic membrane extract polypeptide hydrogel, comprising the following steps: at 0°C, mixing the amniotic membrane extract obtained in Preparation Example 2 with a polypeptide aqueous solution containing 2% by mass of the polypeptide, the volume ratio of the amniotic membrane extract to the polypeptide solution being 1:2, and the polypeptide being biotin-FYIGSRGD.

[0079] Example 3

[0080] This example prepares an amniotic membrane extract polypeptide hydrogel, comprising the following steps: at 8° C., the amniotic membrane extract obtained in Preparation Example 3 is mixed with a polypeptide aqueous solution containing 0.5% of the polypeptide by mass, the volume ratio of the amniotic membrane extract to the polypeptide solution is 1:4, and the polypeptide is biotin-FYIGSRGD.

[0081] Embodiment 4-7

[0082] This example prepared an amniotic membrane extract polypeptide hydrogel, which differed from Example 1 only in that the amniotic membrane extract obtained in Preparation Examples 4-7 was mixed with the polypeptide aqueous solution.

[0083] Example 8

[0084] This example prepared an amniotic membrane extract polypeptide hydrogel, which was different from Example 1 only in that the volume ratio of the amniotic membrane extract to the polypeptide solution was 1:1.

[0085] Example 9

[0086] This example prepared an amniotic membrane extract polypeptide hydrogel, which was different from Example 1 only in that the volume ratio of the amniotic membrane extract to the polypeptide solution was 1:5.

[0087] Example 10

[0088] This example prepared an amniotic membrane extract polypeptide hydrogel, which differed from Example 1 only in that the carboxyl end of the polypeptide was connected to IGF1.

[0089] Embodiment 11

[0090] This example prepared an amniotic membrane extract polypeptide hydrogel, which differed from Example 1 only in that the amino acid sequence of the polypeptide was shown in SEQ ID NO.2, SEQ ID NO.2: biotin-YIGSRGD.

[0091] Comparative Example 1-2

[0092] This comparative example prepared an amniotic membrane extract polypeptide hydrogel, which differs from Example 1 only in that the amniotic membrane extract obtained in Comparative Preparation Example 1-2 was mixed with the polypeptide aqueous solution.

[0093] Test Example 1

[0094] In this test example, the contents of hepatocyte growth factor (HGF) and heavy chain-hyaluronic acid / pentin 3 (HC-HA / PTX3) were measured in the amniotic membrane extracts prepared in Preparation Examples 1-7 and Comparative Preparation Examples 1-2. The results are shown in Table 1.

[0095] Table 1

[0096] Group HGF content (ng / mL) <![CDATA[HC-HA / PTX3 content (×10 5 ng / mL)]]> Preparation Example 1 94.5 6.80 Preparation Example 2 69.8 5.08 Preparation Example 3 140.5 9.98 Preparation Example 4 82.9 6.16 Preparation Example 5 80.4 6.12 Preparation Example 6 79.6 6.01 Preparation Example 7 80.8 6.12 Comparative Preparation Example 1 49.6 3.64 Comparative Preparation Example 2 70.4 4.84

[0097] As can be seen from Table 1, since the fibroblast layer and sponge layer of the amniotic membrane contain less active ingredients, removing them during the preparation process helps to increase the concentration of the active ingredients. The manual scraping method may leave the fibroblast layer and sponge layer, or may remove tissues other than the fibroblast layer and sponge layer, so the content of the active ingredient is reduced. Comparing Preparation Example 1 with Preparation Examples 4-7, it can be seen that suitable freeze-thaw conditions help to completely remove the fibroblast layer and sponge layer and reduce residues.

[0098] Test Example 2

[0099] In this test example, the amniotic membrane extract polypeptide hydrogel prepared in Example 1 was observed under an electron microscope. Figure 1 As shown, the tubular structure is the polypeptide hydrogel, and the granular substance is the amniotic membrane extract. It can be seen that the amniotic membrane extract is wrapped by the polypeptide hydrogel. Figure 2 This is a photo of the amniotic membrane extract polypeptide hydrogel prepared in Example 1, which is clear and transparent, and does not flow when tilted, and is in a gel-like state.

[0100] Test Example 3

[0101] In this test example, the transparency of the amniotic membrane extract polypeptide hydrogel prepared in Example 1 was tested. The amniotic membrane extract polypeptide hydrogel was added to a 96-well plate (100 μL / well), and the absorbance was measured at wavelengths of 400 nm, 500 nm, 600 nm, 700 nm and 800 nm using a spectrometer at room temperature, and physiological saline was used as a blank control.

[0102] The results are as follows Figure 3 As shown, there is no obvious difference in transparency between the amniotic membrane extract polypeptide hydrogel and normal saline. When the amniotic membrane extract polypeptide hydrogel is used as a drug for treating corneal damage, patients apply it to the eyes. Due to the good transparency of the drug, the patient's troubles caused by obstruction of vision during use are reduced, thereby improving the patient's compliance with drug use.

[0103] Test Example 4

[0104] In this test example, the biocompatibility of the amniotic membrane extract polypeptide hydrogel prepared in Examples 1, 8 and 9 was tested, and the amniotic membrane extract prepared in Preparation Example 1 and a polypeptide solution with a polypeptide mass percentage of 1% (the polypeptide is biotin-FYIGSRGD) were used as the control group to conduct a CCK-8 experiment.

[0105] Experimental steps:

[0106] (1) Cell culture: The HEK293 cell line was selected and the cells were seeded into a 96-well plate with approximately 1×10 cells per well. 4 The cells were cultured at 37°C, 5% CO2 for 24 hours to allow them to adhere.

[0107] (2) Treatment: After 24 hours, add an equal amount of drug to the cell culture medium. Set up 3-5 replicate wells for each treatment to ensure the reliability of the results. Continue to culture the cells for 24-48 hours.

[0108] (3) Add CCK-8 reagent: Add 10 μL of CCK-8 reagent to each well and incubate at 37°C for 4 h.

[0109] (4) Determine absorbance: Use an ELISA reader to measure the absorbance of each well at 450 nm. The absorbance value is proportional to the number and viability of cells.

[0110] (5) Data analysis: Calculate the average absorbance value of each group, use the absorbance value of the untreated group as a reference, and calculate the relative value of cell viability in the treated group.

[0111] The test results are shown in Table 2. The biocompatibility of the amniotic membrane extract polypeptide hydrogel is better than that of the amniotic membrane extract or polypeptide hydrogel alone, and the specific ratio of the amniotic membrane extract to the polypeptide aqueous solution can improve its biocompatibility.

[0112] Table 2

[0113] Group Cell viability Example 1 1.15 Example 8 1.07 Example 9 1.02 Amniotic membrane extract 1.04 Peptide hydrogel 1.01

[0114] Test Example 5

[0115] This test example tests the preservation of the active pharmaceutical ingredients of the amniotic membrane extract polypeptide hydrogel and amniotic membrane extract obtained in Examples 1-11 and Comparative Examples 1-2 at different temperatures to prove that the active ingredients of the amniotic membrane extract polypeptide hydrogel are very stable. The experimental temperatures are -20°C, 4°C and 26°C, 9 samples per group, 3 samples per group in each temperature environment, and the HGF content at 0 days and 21 days is measured. Preparation Example 1 without adding polypeptide is used as the control group. The test results are shown in Table 3.

[0116] Table 3

[0117]

[0118]

[0119] As can be seen from Table 3, the HGF content of the control group gradually decreased over time, and Example 1 also decreased, but the downward trend was not obvious. It can be seen that the active ingredients of the amniotic membrane extract polypeptide hydrogel are well maintained, and the HGF content is relatively stable even at room temperature. Comparing Example 1 with Examples 8 and 9, it can be seen that in the amniotic membrane extract polypeptide hydrogel, if the proportion of polypeptide hydrogel is too small, the amniotic membrane extract cannot be completely coated, and the active ingredients decrease over time; while if the proportion of polypeptide hydrogel is too large, there is no significant effect on the change in the content of the active ingredient of the drug, but the active ingredient of the drug is less, which is not conducive to its therapeutic effect. Comparing Example 1 with Examples 10 and 11, it can be seen that the type of polypeptide will affect the structure of the formed polypeptide hydrogel, thereby affecting the preservation of the active ingredient of the drug.

[0120] Test Example 6

[0121] In this test example, the amniotic membrane extract polypeptide hydrogel obtained in Example 1 was tested for its effect on promoting corneal repair at the cellular level, and a corneal epithelial cell scratch experiment was conducted, which specifically included the following steps: 1×10 5 The corneal epithelial cells were seeded in a 12-well plate at a density of cells / well. When the cells grew to 90%, a wound was formed in the middle of the monolayer with a 1 mL pipette tip. The damaged cells were washed with PBS, and the remaining cells were added to the amniotic membrane extract polypeptide hydrogel and continued to be cultured. The control group was composed of the amniotic membrane extract prepared in Preparation Example 1, a polypeptide aqueous solution with a polypeptide mass percentage of 1% (the polypeptide was biotin-FYIGSRGD), and a standard culture medium. The wound healing status was photographed and recorded at predetermined time intervals, and the experiment was repeated three times to ensure the authenticity and reliability of the results. The results are as follows: Figure 4 As shown, the amniotic membrane extract polypeptide hydrogel group has a good effect on promoting cell growth and migration.

[0122] Test Example 7

[0123] In this test example, 0.05 mL of the amniotic membrane extract polypeptide hydrogel obtained in Example 1 was immersed in 1 mL of normal saline and placed in a 36.5°C environment (simulating human body temperature). 200 μL of the supernatant was taken out at regular intervals and replaced with an equal amount of normal saline. The HGF content of the supernatant was determined by ELISA method, and the samples were taken every 30 minutes for the first 6 hours. The sampling process and the process of adding normal saline must be gentle to avoid operating actions that accelerate the release of the drug. The test results are as follows: Figure 5 As shown, it can be seen that the active pharmaceutical ingredient is released steadily and slowly.

[0124] Test Case 8

[0125] In this test example, the amniotic membrane extract polypeptide hydrogel obtained in Example 1 was tested for its drug colloid properties. The testing instrument was a torque rheometer MCR302 (Anton Paar, Austria), and the testing temperature was 25°C. The alternating strain scanning test used a torque rheometer equipped with a flat bottom plate and a conical rotor (25 mm in diameter) to test rheological properties. High shear strain (100%) and low shear strain (1%) were applied alternately for 4 cycles at a constant frequency of 1 Hz. The storage modulus and loss modulus of the polypeptide hydrogel were observed to change over time under high and low shear strains. The stress scanning test scan range was set to 0.01%-1000%, and the frequency was constant at 1 Hz. The changes in the mechanical properties of the test colloid with stress changes were measured to obtain the colloid elastic modulus and viscous modulus change curves.

[0126] Figure 6 The figure shows the changes of elastic modulus and viscous modulus under different stresses. There is no obvious change in the elastic modulus and viscous modulus under different stresses, which shows that the colloid has good structural stability. Figure 7 The figure shows the change of storage modulus and loss modulus with time under alternating high and low shear strains. When high shear strain and low shear strain are applied alternately, the storage modulus and loss modulus of the colloid recover quickly, indicating that the colloid has good self-healing ability.

[0127] In summary, the present invention provides a method for preparing an amniotic membrane extract, and obtains a homogeneous and transparent amniotic membrane extract, which does not require excessive processes such as chemical treatment, has simple operation steps, and retains the active ingredients of the amniotic membrane to the greatest extent. The present invention mixes the amniotic membrane extract with a polypeptide solution to prepare an amniotic membrane extract polypeptide hydrogel, which uses the polypeptide hydrogel to preserve the active ingredients of the drug and achieve sustained release of the drug, providing the possibility of clinical application of amniotic membrane to promote corneal damage repair.

[0128] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.

Claims

1. A method for preparing an amniotic membrane extract, characterized in that: The preparation method of the amniotic membrane extract comprises: tearing off the fibroblast layer and the sponge layer after freezing and thawing the amniotic membrane, freezing the remaining tissue in liquid nitrogen, grinding to obtain amniotic membrane powder, mixing with physiological saline, filtering and centrifuging to obtain the supernatant, and obtaining the amniotic membrane extract.

2. The method for preparing the amniotic membrane extract according to claim 1, characterized in that: The freezing temperature during the freeze-thaw process is -20 to -40°C; Preferably, the freezing time during the freeze-thaw process is 12 to 20 hours; Preferably, the temperature rise rate of thawing during the freeze-thaw process is 0.5-1°C / min; Preferably, the final thawing temperature during the freeze-thaw process is 0-8°C.

3. The method for preparing the amniotic membrane extract according to claim 1 or 2, characterized in that: The step of flushing the amniotic membrane with a composite solution before freezing and thawing the amniotic membrane is also included; Preferably, the composite solution contains 50-150 μg / mL gentamicin and 20-30 μg / mL amphotericin B; Preferably, after freezing and thawing the amniotic membrane, the method further comprises the step of flushing with physiological saline to remove the composite solution.

4. The method for preparing the amniotic membrane extract according to any one of claims 1 to 3, characterized in that: Before filtering, the mixed solution of amniotic membrane powder and physiological saline is mixed at 0-8°C and 80-120r / min for 40-55h; Preferably, the ratio of the amniotic membrane powder to physiological saline is 1 g: (2-4) mL; Preferably, the pore size of the filtration membrane is 50-100 μm.

5. The method for preparing the amniotic membrane extract according to any one of claims 1 to 4, characterized in that: The centrifugal speed is 2000-4000 r / min; Preferably, the centrifugation time is 10 to 20 minutes; Preferably, the centrifugation temperature is 22-28°C.

6. An amniotic membrane extract, characterized in that The amniotic membrane extract is prepared by the method for preparing the amniotic membrane extract according to any one of claims 1 to 5.

7. An amniotic membrane extract polypeptide hydrogel, characterized in that: The amniotic membrane extract polypeptide hydrogel contains the amniotic membrane extract according to claim 6 and a polypeptide solution.

8. The amniotic membrane extract polypeptide hydrogel according to claim 7, characterized in that: The mass percentage of the polypeptide in the polypeptide solution is 0.5% to 2%; Preferably, the amino acid sequence of the polypeptide includes the sequence shown in SEQ ID NO.1; Preferably, the volume ratio of the amniotic membrane extract to the polypeptide solution is 1:(2-4).

9. The amniotic membrane extract polypeptide hydrogel according to claim 7 or 8, characterized in that: The amnion extract polypeptide hydrogel is prepared by the following preparation method: stirring and mixing the amnion extract and the polypeptide solution at 0-8°C.

10. Use of any one of the preparation method of the amniotic membrane extract according to any one of claims 1 to 5, the amniotic membrane extract according to claim 6, or the amniotic membrane extract polypeptide hydrogel according to any one of claims 7 to 9, or a combination of at least two thereof, in the preparation of a drug for treating eye diseases; Preferably, the eye disease includes any one or a combination of at least two of corneal injury, Sjögren's syndrome, dry eyes, corneal ulcer, chemical burns of the cornea and conjunctiva, or corneal erosion.

Citation Information

Patent Citations

  • Pharmaceutical amniotic membrane and processes for their prepn.

    CN101040616A